当前位置: X-MOL 学术J. Alzheimer’s Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
Journal of Alzheimer’s Disease ( IF 4 ) Pub Date : 2021-09-09 , DOI: 10.3233/jad-210614
Elisa Colato 1 , Konstantinos Chiotis 1, 2 , Daniel Ferreira 1 , Mariam S Mazrina 1 , Laetitia Lemoine 1 , Rosaleena Mohanty 1 , Eric Westman 1 , Agneta Nordberg 1, 3 , Elena Rodriguez-Vieitez 1 ,
Affiliation  

Abstract

Background:

In Alzheimer’s disease (AD), the abnormal aggregation of hyperphosphorylated tau leads to synaptic dysfunction and neurodegeneration. Recently developed tau PET imaging tracers are candidate biomarkers for diagnosis and staging of AD.

Objective:

We aimed to investigate the discriminative ability of 18F-THK5317 and 18F-flortaucipir tracers and brain atrophy at different stages of AD, and their respective associations with cognition.

Methods:

Two cohorts, each including 29 participants (healthy controls [HC], prodromal AD, and AD dementia patients), underwent 18F-THK5317 or 18F-flortaucipir PET, T1-weighted MRI, and neuropsychological assessment. For each subject, we quantified regional 18F-THK5317 and 18F-flortaucipir uptake within six bilateral and two composite regions of interest. We assessed global brain atrophy for each individual by quantifying the brain volume index, a measure of brain volume-to-cerebrospinal fluid ratio. We then quantified the discriminative ability of regional 18F-THK5317, 18F-flortaucipir, and brain volume index between diagnostic groups, and their associations with cognition in patients.

Results:

Both 18F-THK5317 and 18F-flortaucipir outperformed global brain atrophy in discriminating between HC and both prodromal AD and AD dementia groups. 18F-THK5317 provided the highest discriminative ability between HC and prodromal AD groups. 18F-flortaucipir performed best at discriminating between prodromal and dementia stages of AD. Across all patients, both tau tracers were predictive of RAVL learning, but only 18F-flortaucipir predicted MMSE.

Conclusion:

Our results warrant further in vivo head-to-head and antemortem-postmortem evaluations. These validation studies are needed to select tracers with high clinical validity as biomarkers for early diagnosis, prognosis, and disease staging, which will facilitate their incorporation in clinical practice and therapeutic trials.



中文翻译:

通过 18F-THK5317 和 18F-Flortaucipir PET 测量的 Tau 病理学评估及其与阿尔茨海默病脑萎缩和认知的关系

摘要

背景:

在阿尔茨海默病 (AD) 中,过度磷酸化 tau 的异常聚集导致突触功能障碍和神经变性。最近开发的 tau PET 成像示踪剂是 AD 诊断和分期的候选生物标志物。

客观的:

我们旨在研究18 F-THK5317 和18 F-flortaucipir 示踪剂在 AD 不同阶段的辨别能力和脑萎缩,以及它们各自与认知的关联。

方法:

两个队列,每个队列包括 29 名参与者(健康对照 [HC]、前驱 AD 和 AD 痴呆患者),接受了18 F-THK5317 或18 F-flortaucipir PET、T1 加权 MRI 和神经心理学评估。对于每个受试者,我们量化了六个双边和两个复合感兴趣区域内的区域18 F-THK5317 和18 F-flortaucipir 摄取。我们通过量化脑容量指数来评估每个人的整体脑萎缩,脑容量指数是衡量脑容量与脑脊液比率的指标。然后,我们量化区域的甄别能力18架F-THK5317,18架F-flortaucipir和脑容量诊断组之间及其与患者认知协会指数,和。

结果:

这两个18 F-THK5317和18架F-flortaucipir在HC和两个前驱症状的AD和AD痴呆组之间进行区分跑赢全球脑萎缩。18 F-THK5317 在 HC 和前驱 AD 组之间提供了最高的区分能力。18 F-flortaucipir 在区分 AD 的前驱期和痴呆阶段方面表现最佳。在所有患者中,两种 tau 示踪剂均可预测 RAVL 学习,但只有18 F-flortaucipir 可预测 MMSE。

结论:

我们的结果保证了进一步的体内头对头和死前-死后评估。这些验证研究需要选择具有高临床有效性的示踪剂作为早期诊断、预后和疾病分期的生物标志物,这将有助于将它们纳入临床实践和治疗试验。

更新日期:2021-09-12
down
wechat
bug